Fertility Testing Devices Market (2025 - 2033)

Fertility Testing Devices Market Summary

The global fertility testing devices market size was estimated at USD 2.47 billion in 2024 and is expected to reach USD 4.71 billion by 2033, growing at a CAGR of 7.50% from 2025 to 2033. Rising awareness about fertility health, delayed parenthood and lifestyle changes, technological advancements in home testing devices, and preference for at-home and non-invasive testing are some of the factors driving industry growth.

Furthermore, the growth of IVF and other ART procedures encourages pre-conception monitoring using fertility devices, thereby escalating market growth. Many women are choosing to start families later due to career priorities, higher education, and personal goals. Delaying parenthood can affect fertility, leading to increased interest in monitoring reproductive health.

The table shows a clear shift toward older maternal ages, with the proportion of first births among women aged 30-34 and 35+ steadily increasing from 2016 to 2023, highlighting delayed parenthood and supporting the growing demand for fertility testing devices.

Percentage of first births, by age of mother: U.S., 2018 - 2023

Source: National Center for Health Statistics, National Vital Statistics System, natality data file

In addition to delayed parenthood, lifestyle factors significantly impact reproductive health for both men and women. High stress levels, irregular sleep patterns, poor dietary habits, limited physical activity, and smoking reduce fertility in men and women. Smoking in men has been linked to reduced sperm count, motility, and overall semen quality, while in women, it affects ovarian reserve and conception rates. For instance, as per the Global Action to End Smoking, in 2022, approximately 253.0 million individuals (200.2 million males and 53.5 million females) aged 15 and above were users of tobacco products in India. These lifestyle challenges have led many individuals to actively monitor their reproductive health through home-based and non-invasive fertility testing devices.

Furthermore, the increasing prevalence of infertility worldwide has boosted demand for fertility testing devices for both men and women. A WHO report published in 2023 states that about 17.5% of adults, roughly 1 in 6 people globally, face infertility, emphasizing the critical need for improved access to affordable, high-quality care for those affected. Contributing factors include hormonal imbalances, reproductive conditions like polycystic ovary syndrome (PCOS) in women, and decreasing sperm quality in men.

Annual Incidence Rates of Female Infertility Diagnoses by Age Group, Active Component Service Women, U.S. Armed Forces, 2019-2023

Market Concentration & Characteristics

The industry has seen significant innovation over the past decade, driven by the demand for home-based, non-invasive, and accurate reproductive health monitoring. Modern ovulation prediction kits now incorporate digital sensors, smartphone connectivity, and AI-powered cycle tracking, allowing users to receive personalized fertility insights. For instance, Clearblue Advanced Fertility Monitor tracks both luteinizing hormone (LH) and estradiol (E3G), improving prediction accuracy by up to 99% for peak fertility days. Moreover, male fertility testing has also advanced, with devices such as Yo Home Sperm Test providing smartphone-based sperm motility and concentration analysis at home, showing over 95% correlation with laboratory semen analysis.

The level of mergers and acquisitions in the market remains relatively low, with few recent deals observed. Most companies focus on organic growth through product innovation and expansion of at-home and digital fertility solutions rather than consolidation.

Agencies such as the U.S. Food and Drug Administration (FDA) and the European Medicines Agency (EMA) classify ovulation prediction kits, fertility monitors, and home semen analysis devices as medical devices, requiring clearance or approval before market launch. Compliance with such regulations increases consumer trust but may slow product launch timelines, impacting market growth, especially for emerging home-based devices.

Several market players are expanding their business by introducing new products. For instance, in August 2023, Trajan Scientific and Medical supplied CE-IVD registered Mitra devices to Fertilly, a German start-up, which launched Europe’s first at-home fertility test kits using dried blood microsampling with VAMS technology.

Product Insights

The ovulation prediction kits segment led the market in 2024 with a 42.05% share. Growing awareness among women and couples about reproductive health and fertility planning is driving market growth. Delayed parenthood and increasing infertility rates are boosting reliance on home-based ovulation monitoring to optimize the timing of conception. These kits are non-invasive, convenient, and increasingly integrated with digital health platforms, enabling users to track cycles accurately and receive personalized insights. Additionally, technological advances such as smartphone connectivity, enhanced hormone detection sensitivity, and user-friendly interfaces have improved kit accuracy and ease of use.

The male fertility testing devices segment is expected to grow significantly over the forecast period, due to increasing awareness about male reproductive health and the rising prevalence of male infertility. For instance, according to a study released in J Clin Med in 2025, male infertility is a common issue impacting about 15% of couples globally. Factors such as delayed parenthood, lifestyle-related issues such as obesity, smoking, and alcohol consumption, and environmental exposures have further highlighted the need for accessible at-home and clinical testing solutions. In addition, technological advancements, including microfluidic semen analysis, smartphone-integrated devices, and rapid motility and sperm concentration detection kits, have improved convenience, accuracy, and affordability for consumers.

Application Insights

The female fertility testing segment dominated the market in 2024, driven by the increased availability and affordability of advanced diagnostic technologies. Innovations such as high-sensitivity hormone assays, self-collected blood microsampling, and rapid follicle-stimulating hormone (FSH) and anti-Müllerian hormone (AMH) tests enable women to evaluate ovarian reserve and reproductive health with clinical precision from home. Additionally, integration with digital health platforms allows for automated result interpretation, trend tracking, and teleconsultations, further boosting adoption. Moreover, rising infertility rates among women are fueling segment growth. For example, a 2023 study published in the International Journal of Reproduction, Contraception, Obstetrics, and Gynecology found that among infertile women, 57.33% experienced primary infertility, while 42.66% had secondary infertility, with the 26-30 age group being most affected, emphasizing the need for early and accurate assessment.

The male fertility testing segment is expected to grow at the fastest CAGR over the forecast period. Factors such as declining sperm counts, hormonal imbalances, and increasing prevalence of lifestyle-related infertility have prompted men to seek early and convenient diagnostic solutions. As per the 2022 NIH report, human sperm counts have decreased by over 50% worldwide in the last five decades, highlighting the need for timely testing. Furthermore, technological innovations, including home-based semen analysis kits and microfluidic sperm testing devices, allow men to assess motility, concentration, and morphology without visiting clinics, reducing social stigma and encouraging proactive health monitoring, thereby driving industry growth.

End-use Insights

The home care settings segment accounted for the largest share of 44.46% in 2024 due to rising preference for convenient, non-invasive, and private fertility monitoring solutions. Increasing awareness about reproductive health, coupled with the desire to track ovulation, hormone levels, and sperm quality in the comfort of one’s home, is driving adoption of at-home fertility testing devices. In addition, advancements in device accuracy, ease of use, and integration with digital health platforms have enhanced user confidence and engagement. Moreover, rising internet penetration and e-commerce availability have expanded access to these devices, making home-based fertility care an increasingly viable and preferred option.

Fertility clinics are expected to grow at the fastest CAGR over the forecast period, owing to increasing demand for specialized reproductive healthcare and advanced assisted reproductive technologies (ART). Fertility clinics offer comprehensive services, including ovulation induction, in vitro fertilization (IVF), intrauterine insemination (IUI), and hormone monitoring, attracting patients seeking personalized care. The expansion of insurance coverage and reimbursement policies in certain regions has further increased accessibility to clinic-based treatments. Moreover, increased female workforce participation and delayed parenthood trends have also contributed to higher patient volumes, thus supplementing industry growth.

Regional Insights

The North America fertility testing devices market is expected to register significant growth over the forecast period, owing to the high awareness of reproductive health and the widespread availability of advanced assisted reproductive technologies (ART). Moreover, supportive insurance coverage in certain states and growing telehealth adoption for reproductive health consultations have further enhanced accessibility to fertility testing devices.

U.S. Fertility Testing Devices Market Trends

The U.S. fertility testing devices industry accounted for the largest share in North America due to the increasing use of personalized fertility care and demand for early detection tools. Fertility testing devices that provide rapid hormone or sperm analysis at home are becoming popular, especially among millennials seeking convenience and privacy. Moreover, partnerships between device manufacturers and telehealth platforms are facilitating remote consultations and continuous monitoring, further driving adoption.

Asia Pacific Fertility Testing Devices Market Trends

Asia Pacific dominated the industry in 2024 with a share of 36.76%, due to rising awareness, cultural shifts, and increasing adoption of fertility care services. Furthermore, growing urbanization, delayed marriage, and lifestyle changes such as smoking and poor diet are driving demand for both male and female fertility testing devices.

The India fertility testing devices market dominated the Asia Pacific market due to a rise in lifestyle-related infertility. According to an article published in the Indian Journal of Community Medicine in 2024, the prevalence of infertility in India ranges from 3.9% to 16.8%.

The China fertility testing devices marketis expected to register significant growth over the forecast period in Asia Pacific market owing to the rising prevalence of infertility, government initiatives promoting reproductive health, and increasing awareness among working women. Fertility clinics and home-based testing devices are witnessing higher adoption due to privacy preferences and convenience, alongside expansion of ART services.

Europe Fertility Testing Devices Market Trends

Europe held a substantial revenue share of the global industry owing to the rising investments in reproductive healthcare infrastructure and public awareness campaigns about fertility preservation. Furthermore, growing government support, coupled with increasing lifestyle related issues, is driving market growth.

The Germany fertility testing devices marketdominated the Europe industry owing to the widespread health insurance coverage for fertility testing and advanced clinical infrastructure. Moreover, the increasing infertile population in the region is driving market growth. For instance, as per an article published in Deutsche Welle in 2024, infertility affects 1 in 6 women in Germany.

The UK fertility testing devices market is one of the largest markets in Europe and is expected to witness lucrative growth owing to the rising prevalence of age-related infertility among women over 30, coupled with growing awareness of male reproductive health. Increased awareness of ovarian reserve testing and non-invasive hormone monitoring has encouraged both at-home and clinic-based fertility testing, particularly among professionals balancing career and family planning.

Latin America Fertility Testing Devices Market Trends

The industry in Latin America is expected to register considerable growth over the forecast period owing to the increasing investment in reproductive health, expanding private healthcare facilities, and rising awareness about infertility. In countries such as Brazil and Mexico, cultural stigma around fertility is gradually declining, prompting more individuals to seek testing and treatment.

The Brazil fertility testing devices marketis expected to register significant growth over the forecast period in Latin America market. The growth of private fertility clinics offering complementary diagnostic services has stimulated interest in pre-clinic at-home testing to prepare patients for consultations.

Middle East & Africa Fertility Testing Devices Market Trends

The industry in the Middle East & Africa (MEA) is driven by rising awareness of fertility health, adoption of advanced reproductive technologies, and high-income urban populations seeking personalized healthcare solutions. In countries such as UAE and Saudi Arabia, government initiatives to improve maternal and reproductive health, alongside rising investment in private fertility clinics, have driven device adoption.

Key Fertility Testing Devices Company Insights

Key companies in the market are engaged in adopting strategies such as mergers and acquisitions, new service launches, partnerships, collaborations, and expansion to strengthen their position in the market.

Recent Developments

• In December 2023, Bengaluru-based start-up Arva Health launched an at-home fertility test designed to help women track and monitor up to 12 hormone levels affecting fertility. The product is customized specifically for Indian women suffering from polycystic ovary syndrome (PCOS) and thyroid issues, offering a more affordable alternative to traditional fertility clinics.

• In July 2023, Quest Diagnostics partnered with Proov to introduce the Proov Confirm PdG home fertility test on QuestHealth.com. The Proov Confirm PdG test was the FDA-cleared home kit designed to confirm successful ovulation by detecting pregnanediol glucuronide (PdG), a progesterone metabolite, in urine.

• In August 2021, Inito launched its at-home fertility test in the U.S. market. The device, paired with a smartphone app, measures actual hormone levels, estrogen, luteinizing hormone, and progesterone, to provide users with data to guide decisions through the conception process.

Fertility Testing Devices Market